Skip to main content

An Innovative Mass Spectrometry-Based Workflow for Drug Discovery

Project description

Drug discovery efforts for pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a rare disorder associated with high blood pressure in the vessels that supply the lungs. Most drugs address the induced vasoconstriction caused by the narrowing or obstruction in the small arteries in the lung. Recent evidence indicates that inhibitors against Rho-associated protein kinases (ROCKs) may benefit PAH patients by targeting vascular remodelling and inflammation in the lungs. The scope of the EU-funded MS4Drug project is to characterise the conformational changes in ROCKs in vitro as well as in the cellular environment induced by such inhibitors. Alongside investigation into the molecular mechanisms underlying the signalling pathways of ROCKs, researchers hope to design improved drugs for PAH.


Net EU contribution
€ 171 473,28
Via Palermo 26/a
43122 Parma

See on map

Nord-Est Emilia-Romagna Parma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00